BTIG Research Lowers Boston Scientific (NYSE:BSX) Price Target to $56.00

Key Points

• BTIG Research cut Boston Scientific’s price target from $60 to $56 while maintaining a “buy” rating, implying 24.44% upside from the reported $45 share price.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $71.46. Boston Scientific also reported quarterly EPS and revenue above expectations and authorized a $5 billion share buyback.
• A cyberattack disrupted manufacturing and shipments worldwide, putting third-quarter and full-year 2026 guidance at risk. The company has not issued replacement targets, leaving investors focused on the pace of operational recovery and the resulting earnings impact.

Boston Scientific (NYSE:BSX - Get Free Report) had its price target lowered by analysts at BTIG Research from $60.00 to $56.00 in a report released on Wednesday, Benzinga reports. The brokerage presently has a "buy" rating on the medical equipment provider's stock. BTIG Research's price objective indicates a potential upside of 24.44% from the company's current price.

Other research analysts have also issued research reports about the stock. Raymond James Financial reaffirmed an "outperform" rating and set a $57.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Truist Financial dropped their target price on shares of Boston Scientific from $62.00 to $57.00 and set a "buy" rating for the company in a report on Thursday, July 30th. Oppenheimer cut their target price on Boston Scientific from $90.00 to $85.00 and set an "outperform" rating on the stock in a research report on Monday, July 27th. Bank of America lowered their price target on Boston Scientific from $105.00 to $68.00 and set a "buy" rating for the company in a research report on Monday, May 18th. Finally, Evercore set a $65.00 price objective on Boston Scientific in a research note on Monday, July 6th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Boston Scientific has an average rating of "Moderate Buy" and a consensus price target of $71.46.

Boston Scientific Stock Performance

NYSE:BSX opened at $45.00 on Wednesday. The company's 50-day moving average is $47.04 and its two-hundred day moving average is $55.18. Boston Scientific has a 1-year low of $42.20 and a 1-year high of $109.50. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The firm has a market capitalization of $65.22 billion, a price-to-earnings ratio of 18.22, a PEG ratio of 1.10 and a beta of 0.57.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the previous year, the company earned $0.75 EPS. The business's revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts forecast that Boston Scientific will post 3.3 EPS for the current year.

Boston Scientific announced that its board has initiated a share buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback programs are often an indication that the company's leadership believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney acquired 186,240 shares of the business's stock in a transaction dated Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares of the company's stock, valued at $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig bought 5,000 shares of the firm's stock in a transaction that occurred on Friday, July 31st. The stock was bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director owned 30,359 shares of the company's stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 194,522 shares of company stock valued at $9,385,210 in the last 90 days. Company insiders own 0.34% of the company's stock.

Institutional Investors Weigh In On Boston Scientific

Several large investors have recently bought and sold shares of the stock. Renaissance Group LLC purchased a new stake in shares of Boston Scientific in the fourth quarter valued at $28,064,000. Perigon Wealth Management LLC purchased a new position in Boston Scientific during the second quarter worth about $883,000. Y Intercept Hong Kong Ltd boosted its stake in Boston Scientific by 148.8% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider's stock worth $47,816,000 after buying an additional 670,060 shares during the last quarter. Wealthfront Advisers LLC acquired a new stake in Boston Scientific in the 2nd quarter worth about $3,253,000. Finally, PensionDanmark Pensionsforsikringsaktieselskab grew its holdings in Boston Scientific by 9.9% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider's stock valued at $13,659,000 after buying an additional 28,961 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific said manufacturing, shipping and other global operations are recovering, which could limit the disruption’s duration. The company also continues to point to multiple product launches and cost savings as potential longer-term growth drivers. Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack
• Neutral Sentiment: The company has not provided replacement targets for its third-quarter or full-year 2026 outlook. Investors will likely focus on the pace of operational recovery and the size of the eventual revenue and profit shortfall. Boston Scientific says cyberattack likely to hurt 2026 sales, profit
• Negative Sentiment: The cyberattack disrupted manufacturing and order shipments worldwide, creating a material expected impact on third-quarter and full-year 2026 results. The warning raises the risk of lower sales, reduced operating leverage and an earnings miss relative to prior guidance. Boston Scientific Won't Meet Guidance Due to Cyberattack
• Negative Sentiment: Beyond the immediate cyberattack effects, analysts noted pressure on Boston Scientific’s WATCHMAN and electrophysiology businesses, weakening the company’s 2026 growth outlook. That near-term uncertainty outweighs the longer-term benefit expected from new product launches and cost initiatives. Boston Scientific's 2026 Growth Outlook Weakens

Boston Scientific Company Profile

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company's products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.